Nuvasive Stock Price To Earning

NUVADelisted Stock  USD 42.35  0.85  1.97%   
NuVasive fundamentals help investors to digest information that contributes to NuVasive's financial success or failures. It also enables traders to predict the movement of NuVasive Stock. The fundamental analysis module provides a way to measure NuVasive's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NuVasive stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

NuVasive Company Price To Earning Analysis

NuVasive's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

 = 

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Current NuVasive Price To Earning

    
  51.79 X  
Most of NuVasive's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NuVasive is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Competition

Based on the latest financial disclosure, NuVasive has a Price To Earning of 51 times. This is 100.43% higher than that of the Health Care Equipment & Supplies sector and 25.88% lower than that of the Health Care industry. The price to earning for all United States stocks is 80.33% lower than that of the firm.

NuVasive Price To Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NuVasive's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NuVasive could also be used in its relative valuation, which is a method of valuing NuVasive by comparing valuation metrics of similar companies.
NuVasive is currently under evaluation in price to earning category among its peers.

NuVasive Fundamentals

About NuVasive Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze NuVasive's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NuVasive using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NuVasive based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Consideration for investing in NuVasive Stock

If you are still planning to invest in NuVasive check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NuVasive's history and understand the potential risks before investing.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Global Correlations
Find global opportunities by holding instruments from different markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Money Managers
Screen money managers from public funds and ETFs managed around the world
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios